Simulation Overview

Structured evaluation of SurgiSync optimization

Verentia’s initial simulation work evaluated SurgiSync optimization against a conventional FIFO baseline using 1,236 de-identified real-world surgical encounters across 31 days.

Results are presented to highlight comparative performance, operational relevance, and scenario progression across increasingly flexible simulation conditions.

1,236 cases
De-identified real-world surgical encounters across a 31-day retrospective dataset.
FIFO vs SurgiSync
Structured baseline comparison between conventional FIFO scheduling and SurgiSync optimization.
3 simulation tiers
Conservative, moderate-flexibility, and broad-access envelopes.
Parity + Monte Carlo backed outputs
Displayed results are supported by finalized Python source-of-truth runs and 5,000 paired Monte Carlo pilot replications.

Supporting detail and secondary metrics

Headline results summarize the strongest comparative findings across tiers. Supporting metrics shown below provide additional context for how performance was evaluated within the simulation framework.

Tier 2 · 3 OR
Supporting snapshot: Tier 2 · 3 OR
Pass rate: 58.25%
Gated rows: 720
FIFO total margin: $762,298.50
SurgiSync total margin: $854,433.00
FIFO efficiency: $13.76/min
SurgiSync efficiency: $15.40/min

How these results should be interpreted

These findings are based on retrospective simulation and Monte Carlo stress-testing using 1,236 de-identified real-world surgical encounters across a 31-day operating window. The results are intended to demonstrate structured comparative testing, robustness under repeated pilot sampling, and directional performance signals—not universal generalizability across all facilities or operating environments.

The strongest public interpretation of this work is that Verentia has performed disciplined initial evaluation of SurgiSync optimization, observed reproducible comparative improvements under modeled assumptions, and generated a technical basis for further facility-specific evaluation, collaboration, and real-world testing.

Headline results across three simulation tiers

Tier 1

Conservative envelope

Most constrained scenario. Directional uplift still present across both 1 OR and 3 OR simulations.

1 OR
Margin uplift*
+$21,688.50
Efficiency gain
+9.44%
3 OR
Margin uplift*
+$28,514.50
Efficiency gain
+5.32%
TRS threshold 0.28 · 51.05% pass rate
Tier 2

Moderate flexibility

Broader candidate access produced stronger comparative gains across both configurations.

1 OR
Margin uplift*
+$29,913.50
Efficiency gain
+10.70%
3 OR
Margin uplift*
+$92,134.50
Efficiency gain
+11.92%
TRS threshold 0.50 · 58.25% pass rate
Tier 3

Broadest access / highest uplift

Widest candidate access produced the largest observed comparative uplift across the simulation set.

1 OR
Margin uplift*
+$65,069.50
Efficiency gain
+21.13%
3 OR
Margin uplift*
+$164,920.00
Efficiency gain
+17.96%
TRS threshold 0.75 · 92.72% pass rate
Statistical robustness

Monte Carlo robustness check

5,000 paired 31-day pilots

To evaluate whether the observed optimization effect persisted under repeated pilot sampling, Verentia ran 5,000 paired Monte Carlo simulations of 31-day operating windows. Each replication compared FIFO proxy scheduling against SurgiSync's optimization using identical sampled case pools, cancellation assumptions, turnover assumptions, and effective OR capacity.

Mean efficiency uplift
+17.03%
95% bootstrap CI
+16.92% to +17.14%
Equal-minutes clipped uplift
+$24,157
Mean added cases
+14.9
per 31-day pilot
Monte Carlo output table
Metric FIFO proxy SurgiSync Optimization Difference / uplift
Mean margin per 31-day pilot $142,750 $168,153 +$25,402
Mean margin efficiency $11.67/min $13.64/min +17.03%
Mean OR minutes used 12,234 12,325 +0.76%
Mean scheduled cases 78.8 93.7 +14.9 cases
95% CI for efficiency uplift +16.92% to +17.14%
95% CI for clipped uplift $24,016 to $24,299
Equal-minutes clipped uplift +$24,157
Equal-minutes control: SurgiSync used nearly equivalent OR time versus FIFO, with a mean optimized-minutes difference of +0.76%. When evaluated at FIFO-equivalent minutes, the simulated clipped margin uplift remained positive.
FIFO comparator note: because source queue-entry timestamps were unavailable in the Monte Carlo run, FIFO was modeled as a TRS-jittered first-in scheduling proxy. Both arms were evaluated under identical sampled case pools, cancellation assumptions, turnover assumptions, and effective capacity.
Interpretation: these are simulation outputs and should be interpreted as robustness testing under modeled assumptions, not prospective clinical validation or guaranteed financial performance.
Methodology note

Results are based on retrospective simulation across 1,236 de-identified surgical encounters over a 31-day operating window, comparing FIFO proxy scheduling against SurgiSync optimization under tier-specific TRS thresholds and defined operational constraints. A separate Monte Carlo robustness check used 5,000 paired 31-day pilot replications. In each replication, FIFO and SurgiSync were evaluated under identical sampled case pools, cancellation assumptions, turnover assumptions, and effective OR capacity.

Financial interpretation note

Financial values shown are derived from specialty-aware proxy coefficients used for comparative simulation and prioritization only. They do not represent actual realized reimbursement, profit, or net margin, and should be interpreted as directional financial-efficiency signals.